News
Novo Nordisk Cuts Earning Forecasts Again, Names New CEO
Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, on Tuesday lowered its full-year earnings forecasts again as it unveiled a new chief executive to tackle "recent market challenges".
Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a ...
5hon MSN
Novo Nordisk issues profit warning as competition — legal and otherwise — hits Wegovy, Ozempic
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.
3h
Novo Nordisk stock crashes after company cuts sales, profit outlook on weight loss drug competition
Shares in Danish drugmaker Novo Nordisk were down nearly 20% in pre-market trading Tuesday morning after the company cuts its ...
Novo Nordisk stock collapsed 26% in its worst trading day ever after slashing guidance on Wegovy sales and naming a new CEO.
Partially a result, Novo Nordisk has steadily declined since last summer. Over the past year, NVO shares are down more than ...
A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will ...
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback